DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?

Cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy is standard in fit patients. Inactivating mutations of the nucleotide excision repair gene ERCC2 can predict response to cisplatin-based chemotherapy. Evaluation of the functional impact of ERCC2 mutations can provide mechanistic frameworks supporting the potential predictive role of ERCC2 loss of function.

See related article by Li et al., p. 977

http://bit.ly/2HJoDAb